Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Biomarker Blood Test Offers Diagnostic Potential for HPV-Related Cancers

November 25, 2020
By Hannah Slater
Article

“This might raise the potential of being able to detect disease recurrence much earlier than current clinical practice,” said Thomas Weiland, MD.

HPV16-L1 DRH1 epitope-specific antibodies are linked to HPV16-induced malignant disease, according to results from a multicenter European study published in EBioMedicine.1

These findings are based on a highly specific diagnostic test that appears to indicate cancer and predict its course from just a pinprick of blood. The newly developed HPV16-L1 DRH1 epitope-specific serological assay detects levels of DRH1 to HPV16.

Importantly, HPV16 is the most carcinogenic of the 206 HPV-subtypes identified thus far and accounts for up to 90% of HPV-induced cancer deaths.

“This is the first time that we have been able to show a link between raised levels of this specific antibody and HPV cancers, indicating the course of disease,” Thomas Weiland, MD, of the division of General Otorhinolaryngology in Austria’s Medical University of Graz, said in a press release.2 “This might raise the potential of being able to detect disease recurrence much earlier than current clinical practice.”

This multicenter study was comprised of 1486 patients, including 301 patients with head and neck squamous cell carcinoma (HNSCC), 12 with HIV-positive anal cancer, 80 who were HIV-positive, 29 who were vaccinated with Gardasil-9, and 1064 healthy controls. Participants were tested for human HPV16-L1 DRH1 antibodies using the DRH1-competitive-serological-assay.

Ultimately, the DRH1-competitive-serological-assay demonstrated a sensitivity of 95% (95% CI, 77.2%-99.9%) for HPV16-driven HNSCC, and 90% (95% CI, 55.5%-99. 7%) for HPV16-induced anal cancer in HIV-positive patients. Moreover, overall diagnostic specificity was 99.46% for men and 99.29% for women 30 years or older.

Following HPV vaccination, the observed antibody level increased from an average of 364 ng/ml to 37,500 ng/ml. During post-therapy monitoring, patients with HNSCC showing an antibody decrease in the range of 30% to 100% lived disease free over a period of up to 26 months. Of note, the increase of antibodies from 2750 ng/ml to 12,000 ng/ml mirrored recurrent disease.

In addition, the investigators were also able to show that the L1-capsid protein is expressed in HPV16-DNA positive tumor-tissue.

“While HPV infection does not indicate cancer, scientists have suspected for some time that if antibodies were to develop, there may be a link to cancer,” Ralf Hilfrich, PhD, founder of Abviris and the creator of the DRH1 blood-based HPV tumor marker, said in the release. “Being able to detect that early enough could have a major impact on patient outcomes.”

“The test’s specificity has enabled scientists to show that rising levels of HPV antibodies in blood do reflect malignancy,” Hilfrich added. “The study also indicates that it may prove diagnostically significant, compared to current detection methods, when a biopsy is hard to access, or where the site of the primary cancer is unknown or unidentifiable, such as very early metastasis.”

Overall, these study results provide promising findings, especially when compared to the most effective cancer screening test so far, the Pap-smear, which has significantly reduced the incidence of HPV-induced cervical cancer, even with less impressive key data of about 50% sensitivity and 98% specificity.

References:

1. Weiland T, Eckert A, Tomazic PV, et al. DRH1 – a novel blood-based HPV tumour marker. EBioMedicine. doi: 10.1016/j.ebiom.2020.102804

2. ‘Pinprick’ biomarker blood test offers diagnostic potential in HPV-related cancers Study shows rising antibody levels predict the course of cancer [news release]. Ahrensburg, Germany. Published November 11, 2020. Accessed November 18, 2020. https://www.newswise.com/articles/pinprick-biomarker-blood-test-offers-diagnostic-potential-in-hpv-related-cancers-study-shows-rising-antibody-levels-predict-the-course-of-cancer?sc=dwhr&xy=10019792

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Related Content

The cumulative chronic grade 3 or higher toxicity rate was 3% in patients treated with de-escalated adjuvant radiotherapy vs 11% with standard of care therapy.

DART Therapy Exhibits Greater Tolerability in Oropharyngeal SCC

Roman Fabbricatore
September 5th 2025
Article

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David J. Sher, MD, MPH
September 5th 2025
Podcast

In June 2025, the FDA approved pembrolizumab in the same indication for HNSCC.2

Health Canada Approves Pembrolizumab/Surgery in Locally Advanced HNSCC

Tim Cortese
September 5th 2025
Article

A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck

A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck

Omar K. Abughanimeh, MBBS;Nicole A. Shonka, MD;Jane Meza, PhD;Lynette Smith, PhD;Irfan A. Vaziri, MD;Mehmet Sitki Copur, MD;Robin High, MBA;Kimberly Shields, BSN, RN;Holly DeSpiegelaere, BSN, RN;Anne Kessinger, MD;Apar Kishor Ganti, MD, MS
September 5th 2025
Article

Data from the RATIONALE-309 trial support the European Commission’s approval of frontline tislelizumab plus chemotherapy in this patient population.

Tislelizumab/Chemotherapy Earns EU Approval in Nasopharyngeal Carcinoma

Russ Conroy
September 5th 2025
Article

No tracer-related adverse effects were observed in the study, with [18F]AIF-NOTA-PCP2 showing acceptable dosimetry in patients with head and neck cancers.

[18F]AIF-NOTA-PCP2 Shows PD-L1 Monitoring Potential in Head and Neck Cancer

Roman Fabbricatore
September 5th 2025
Article
Related Content

The cumulative chronic grade 3 or higher toxicity rate was 3% in patients treated with de-escalated adjuvant radiotherapy vs 11% with standard of care therapy.

DART Therapy Exhibits Greater Tolerability in Oropharyngeal SCC

Roman Fabbricatore
September 5th 2025
Article

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David J. Sher, MD, MPH
September 5th 2025
Podcast

In June 2025, the FDA approved pembrolizumab in the same indication for HNSCC.2

Health Canada Approves Pembrolizumab/Surgery in Locally Advanced HNSCC

Tim Cortese
September 5th 2025
Article

A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck

A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck

Omar K. Abughanimeh, MBBS;Nicole A. Shonka, MD;Jane Meza, PhD;Lynette Smith, PhD;Irfan A. Vaziri, MD;Mehmet Sitki Copur, MD;Robin High, MBA;Kimberly Shields, BSN, RN;Holly DeSpiegelaere, BSN, RN;Anne Kessinger, MD;Apar Kishor Ganti, MD, MS
September 5th 2025
Article

Data from the RATIONALE-309 trial support the European Commission’s approval of frontline tislelizumab plus chemotherapy in this patient population.

Tislelizumab/Chemotherapy Earns EU Approval in Nasopharyngeal Carcinoma

Russ Conroy
September 5th 2025
Article

No tracer-related adverse effects were observed in the study, with [18F]AIF-NOTA-PCP2 showing acceptable dosimetry in patients with head and neck cancers.

[18F]AIF-NOTA-PCP2 Shows PD-L1 Monitoring Potential in Head and Neck Cancer

Roman Fabbricatore
September 5th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.